Filing Details
- Accession Number:
- 0001127602-19-017457
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-05-06 16:51:03
- Reporting Period:
- 2019-05-02
- Accepted Time:
- 2019-05-06 16:51:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 882796 | Biocryst Pharmaceuticals Inc | BCRX | Biological Products, (No Disgnostic Substances) (2836) | 621413174 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1230708 | Ii R Thomas Staab | 4505 Emperor Blvd. Suite 200 Durham NC 27703 | Senior Vice President And Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-05-02 | 7,750 | $5.51 | 140,426 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-05-02 | 7,750 | $7.30 | 132,676 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-05-06 | 9,000 | $5.51 | 141,676 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-05-06 | 9,000 | $7.75 | 132,676 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Emp. Stock Option (Right to Buy) | Disposition | 2019-05-02 | 7,750 | $0.00 | 7,750 | $5.51 |
| Common Stock | Emp. Stock Option (Right to Buy) | Disposition | 2019-05-06 | 9,000 | $0.00 | 9,000 | $5.51 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 159,750 | 2018-02-27 | 2027-02-27 | No | 4 | M | Direct |
| 150,750 | 2018-02-27 | 2027-02-27 | No | 4 | M | Direct |
Footnotes
- The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019.
- The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.19 to $7.42. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.43 to $7.86. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Billionaire Hedge Funds
